Ποια είναι η τιμή για Surrozen, Inc. (SRZN)

Η τιμή για Surrozen, Inc. (SRZN) είναι $21.57

Ποια είναι η κεφαλαιοποίηση αγοράς για Surrozen, Inc. (SRZN)

Η κεφαλαιοποίηση αγοράς για Surrozen, Inc. (SRZN) είναι $161.29M

Surrozen, Inc. (SRZN) Τιμή και Κεφαλαιοποίηση Αγοράς

Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6 for the treatment of DME/wet AMD/uveitic macular edema; SZN-113 to treat Fuchs’ endothelial corneal dystrophy and geographic atrophy; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies; and a research collaboration agreement with TCGFB, Inc. to discover antibody therapeutics targeting transforming growth factor beta, or TGF-ß, for the treatment of pulmonary fibrosis. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.

Η τιμή για SRZN	Το περιουσιακό στοιχείο B	Η κεφαλαιοποίηση αγοράς του B	Αποτελέσματα
$689,072 $161.29M	NVDA	$5.152T	+3,194,483.56%
$606,762 $161.29M	AAPL	$4.537T	+2,812,889.45%
$557,486 $161.29M	GOOG	$4.169T	+2,584,445.52%
$487,112 $161.29M	MSFT	$3.642T	+2,258,186.60%
$375,089 $161.29M	AMZN	$2.805T	+1,738,839.00%

Η τιμή για SRZN

Το περιουσιακό στοιχείο B

Η κεφαλαιοποίηση αγοράς του B

Αποτελέσματα

$689,072 $161.29M